Pregnancy in familial hypercholesterolemia needs individualized care

What the study found: Pregnancy in familial hypercholesterolemia requires a stage-specific, individualized approach that balances maternal atherosclerotic cardiovascular disease risk with fetal safety. The review also notes that heterozygous familial hypercholesterolemia usually does not appear to increase major fetal adverse outcomes, while homozygous familial hypercholesterolemia is associated with substantially higher maternal morbidity.
Why the authors say this matters: The authors conclude that pregnant women with familial hypercholesterolemia need timely, multidisciplinary care, and they say expanding pregnancy registries and prospective studies is essential to guide evidence-based care and refine future recommendations. They also note that time off statins is a critical gap in atherosclerotic cardiovascular disease prevention.
What the researchers tested: This was a review that synthesized current evidence, research gaps, and emerging data on lipid-lowering strategies in pregnancy. It also evaluated evolving guideline recommendations for managing familial hypercholesterolemia during pregnancy and lactation.
What worked and what didn't: The review reports that observational data and registry findings indicate heterozygous familial hypercholesterolemia does not significantly increase congenital malformation, prematurity, or low birth weight, although there may be a predisposition to early atherogenesis. It also states that management strategies include dietary optimization, selective use of low-dose statins in high-risk homozygous familial hypercholesterolemia, and LDL apheresis for severe cases, but statins remain contraindicated in most guidelines during pregnancy and lactation despite emerging evidence of no major teratogenic risk.
What to keep in mind: The abstract describes research gaps and says more registry and prospective data are needed. It also indicates that recommendations remain cautious, especially because most guidelines still contraindicate statins in pregnancy and lactation.

Key points

• Pregnancy in familial hypercholesterolemia needs individualized management to balance maternal cardiovascular risk and fetal safety.
• Heterozygous familial hypercholesterolemia does not appear to significantly increase congenital malformation, prematurity, or low birth weight in the cited data.
• Homozygous familial hypercholesterolemia is described as carrying substantially higher maternal morbidity.
• The authors describe dietary optimization, low-dose statins in selected high-risk cases, and LDL apheresis as management strategies.
• Most guidelines still contraindicate statins during pregnancy and lactation despite emerging evidence of no major teratogenic risk.